The DEtection rate of clinically significant PROstate cancer by mpMRI and PSMA-PET/CT fusion biopsy (DEPROMP) trial aims to determine the benefit of additive PET-TB and its impact on the diagnostic and therapeutic algorithm of PCA patients. This evidence concerns the gene FOLH1 and posterior cortical atrophy.